Literature DB >> 12755809

Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU).

Janet Darbyshire1.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12755809      PMCID： PMC1884195          DOI： 10.1046/j.1365-2125.2003.01842.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

1.  The dangers of inferring treatment effects from observational data: a case study in HIV infection.

Authors:  David Dunn; Abdel Babiker; Malcolm Hooker; Janet Darbyshire
Journal:  Control Clin Trials       Date:  2002-04

2.  An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

Authors: 
Journal:  Control Clin Trials       Date:  2001-04

3.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

6.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Authors:  D A Cooper; J M Gatell; S Kroon; N Clumeck; J Millard; F D Goebel; J N Bruun; G Stingl; R L Melville; J González-Lahoz
Journal:  N Engl J Med       Date:  1993-07-29       Impact factor: 91.245

7.  Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

Authors:  J W Mulder; D A Cooper; L Mathiesen; E Sandström; N Clumeck; J M Gatell; M French; B Donovan; F Gray; J M Yeo
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

8.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

9.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.

Authors: 
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.